SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Virgin Galactic Holdings, Inc. is an aerospace and space travel company, which engages in the provision of consumer space experience using reusable spaceflight systems. The firm is also involved in designing, developing, and manufacturing, ground and flight testing, spaceflight operation, and post-flight maintenance of spaceflight systems. The company was founded on May 5, 2017 and is headquartered in Tustin, CA.

Virgin Galactic Holdings Inc - Ordinary Shares - Class A

Virgin Galactic Holdings Inc

Virgin Galactic is experiencing intense retail momentum driven by anticipation surrounding the upcoming SpaceX IPO, with community members actively discussing a potential gamma squeeze. Traders are debating whether the surge represents a genuine short squeeze setup or a temporary meme-driven rally fueled by retail confusion regarding the company's relationship to SpaceX.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is facing intense downward pressure driven by concerns over geopolitical tensions in the Middle East and a notable shift in investor appetite toward surging AI and tech stocks. Market participants are actively debating the sustainability of current price levels, with significant liquidations and sell-offs by major institutional holders fueling concerns about a broader correction.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta is currently trending as the company explores potential entry into the cloud computing market to monetize excess AI infrastructure while rolling out new tiered subscription services for its AI chatbot and social platforms. Investors are closely debating whether these new revenue streams and massive capital expenditures will successfully drive long-term margin expansion or if the stock remains stuck in a consolidation phase amid broader sector volatility.

Strategy, Inc. is a Bitcoin Treasury company. The firm has adopted Bitcoin as a primary treasury reserve asset. It uses proceeds from equity and debt financing, as well as cash flows from operations, to strategically accumulate Bitcoin and advocate for its role as digital capital. Its treasury strategy is designed to provide investors varying degrees of economic exposure to Bitcoin by offering a range of securities, including equity and fixed-income instruments. It provides industry AI-powered enterprise analytics software. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is facing intense scrutiny as a rare sale of Bitcoin holdings and growing concerns over its liquidity and dividend obligations spark a heated debate among investors. The community remains deeply polarized, with critics warning of a potential death spiral while bulls argue that the volatility is merely a tactical opportunity to accumulate positions.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending as retail excitement builds around the upcoming removal of the Pattern Day Trader rule, which investors believe will significantly boost trading volume and engagement. Market sentiment is further bolstered by reports that multiple states are seeking to replicate the federal 'Trump Accounts' program, fueling community speculation about a long-term, government-backed customer acquisition funnel.

Hyperliquid Strategies, Inc. is a holding and operating company, which engages in the business of crypto asset management. The firm operates as a digital asset treasury company which focuses on the Hyperliquid ecosystem. The company was founded on July 2, 2025 and is headquartered in New York, NY.

Hyperliquid Strategies Inc.

Hyperliquid Strategies Inc. (PURR) is seeing a surge in investor attention due to its structural potential for a gamma squeeze, fueled by its low float and integration with the fast-growing Hyperliquid crypto ecosystem. The community is actively debating the stock's role as a unique treasury play while closely monitoring upcoming index inclusions and its performance relative to the HYPE token.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is trending as investors closely monitor the company's progress toward the November FDA PDUFA date for ivonescimab, while positive clinical data from major conferences continues to drive debate over its potential to challenge established immunotherapy standards. The community is actively discussing the stock's significant long-term upside against the backdrop of short-term volatility, with many focused on upcoming interim trial results and the strategic moves of management.

REalloys, Inc. is engaged in the rebuilding of domestic supply chain resilience for rare earth elements and magnets. It is involved in recycling, mining, oxide production, metallization, alloying, and magnet manufacturing. The company was founded on October 4, 2011 and is headquartered in Boca Raton, FL.

REalloys Inc.

REalloys Inc. is trending as the market focuses on its role as the only North American facility currently performing heavy rare-earth metallization, a critical step for U.S. defense supply chains. The stock is generating significant conversation around its strategic position to meet upcoming federal mandates for non-Chinese material sourcing, with the community actively discussing recent bullish analyst coverage and the company's vertically integrated supply chain strategy.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is seeing increased investor attention as a key player in the quantum computing and enterprise AI sectors, fueled by major capital investment plans and its role in U.S. government-backed technology initiatives. Market participants are actively discussing its long-term potential as a quantum leader while debating its recent price momentum and comparing it to other enterprise software and semiconductor plays.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Revolution Medicines is experiencing significant momentum and investor interest following unprecedented Phase 3 data for its pancreatic cancer drug, daraxonrasib, which demonstrated a massive improvement in overall survival. The community is actively discussing the stock's potential as a premier buyout candidate for Big Pharma, with analysts consistently raising price targets and highlighting the company's clear leadership in the high-demand RAS-inhibitor oncology space.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$SLS $MRK $TERN Dr. Khan one of the Phase 2 clinicians, explains the ongoing pivotal randomized SLS PH2B AML-MR Expansion, Front line results, will be even better than the Prior P2B results in end stage setting. 
- this was before Harvard Prof, Dr. Amrein discovered a 3 fold More Potent dosing regime.   
 
- direct link below  
- worth a listen for those buying in now on the market tankage. . . .  
- BUY AND HOLD ALL THAT YOU CAN - your future you will thank you.  
 
Joshua F. Zeidner, MD — University of North Carolina, Lineberger Comprehensive Cancer Center (lead author) 
Omer Jamy — O&#39;Neal Comprehensive Cancer Center, University of Alabama-Birmingham 
Bradley Christensen — Baylor Scott &amp; White Research Institute 
Sharif Khan — Bon Secours Hematology &amp; Oncology 
Dragan Cicic — SELLAS Life Sciences Group 
Tapan Kadia, MD — MD Anderson Cancer Center

David Maibaum

Tony M

5,500% ROI this quarter

Captain

$SLS is it odd - none of the lyin short sbags at work here ever refute the actual facts about Gps and SLS009? 
- 1:47 Minute Mark Dr. Khan discusses the MOS difference for Front Line VS the Prior End Stage  
https://www.reddit.com/r/sellasLifescience/comments/1rkz01h/a_look_back_at_the_rd_day_last_october/?utm_source=share&amp;utm_medium=web3x&amp;utm_name=web3xcss&amp;utm_term=1&amp;utm_content=share_button  
- Cpx-351 Standard of Care offers a 9.7 month Median OS for Newly Diagnosed, AML-MR Patients, w No benefit to Tp53. 
 
- SLS009 Phase 2B AML-MR MOS was Not Reached &gt; 9 months, in Post R/R AML-MR patients who&#39;ve failed AzaVEN - Overall 58% ORR, and 47% for TP53. 
 
Magrolimab - AML-MR Front Line ORR of 63% in a Phase 1B Trial - No Published MOS data. 
- subsequently failed safety. 
Was Bought for $4.9B .  .  . 
Just SLS009 - the &quot;secondary asset&quot;, is already worth - at least the $5B GILD Paid for FTSV - $27 per SLS SHARE - a Direct Head to HEAD Market Cash on the Barrel Comp.  
 
https://www.reddit.com/r/sellasLifescience/comments/1rkz01h/a_look_back_at_the_rd_day_last_october/?utm_source=share&amp;utm_medium=web3x&amp;utm_name=web3xcss&amp;utm_term=1&amp;utm_content=share_button

A Look Back At The R&D Day Last October

StockTwits Web

SELLAS Life Sciences Group Inc

Merck & Co Inc

Terns Pharmaceuticals Inc

 Dr. Khan one of the Phase 2 clinicians, explains the ongoing pivotal randomized SLS PH2B AML-MR Expansion, Front line results, will be even better than the Prior P2B results in end stage setting. 
- this was before Harvard Prof, Dr. Amrein discovered a 3 fold More Potent dosing regime.   
 
- direct link below  
- worth a listen for those buying in now on the market tankage. . . .  
- BUY AND HOLD ALL THAT YOU CAN - your future you will thank you.  
 
Joshua F. Zeidner, MD — University of North Carolina, Lineberger Comprehensive Cancer Center (lead author) 
Omer Jamy — O'Neal Comprehensive Cancer Center, University of Alabama-Birmingham 
Bradley Christensen — Baylor Scott & White Research Institute 
Sharif Khan — Bon Secours Hematology & Oncology 
Dragan Cicic — SELLAS Life Sciences Group 
Tapan Kadia, MD — MD Anderson Cancer Center